menu search

GKOS / Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 5.36% and 5.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? Read More
Posted: Feb 22 2023, 19:34
Author Name: Zacks Investment Research
Views: 110853

GKOS News  

Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

Glaukos Corporation (GKOS) Q3 2023 Earnings Call Transcript

Glaukos Corporation (NYSE:GKOS ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Chris Lewis - Vice President of Inv more_horizontal

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
November 1, 2023

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2023, it might be worth cons more_horizontal

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

By Zacks Investment Research
October 5, 2023

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal

Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics

By Zacks Investment Research
August 2, 2023

Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compar more_horizontal

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

By Zacks Investment Research
July 20, 2023

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal

Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease

By Zacks Investment Research
July 19, 2023

Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease

Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detec more_horizontal

Glaukos: Revising To Buy On These 3 Catalytic Factors

By Seeking Alpha
June 16, 2023

Glaukos: Revising To Buy On These 3 Catalytic Factors

Glaukos Corporation has 3 catalysts to price change going forward. These involve the company's performance, growth, and potential future developments. more_horizontal

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

By Zacks Investment Research
May 19, 2023

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results. more_horizontal


Search within

Pages Search Results: